Abstract: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

Abstract: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

Abstract: The disclosure relates to a pharmaceutical composition for oral administration, containing, as active principle, a benzofuran derivative having antiarrhythmic activity, in particular dronedarone and the pharmaceutically acceptable salts thereof, and at least one lipid carrier, said pharmaceutical composition being intended to be used in unit dosage form of the capsule type, in particular with a hard shell. This pharmaceutical composition and the dosage form comprising such a composition aim to limit the meal time effect following oral administration in humans. The lipid carrier allows: the solubilization of the active principle of the invention; and the shielding thereof from the negative effects of pH in the intestinal tract, thereby allowing same to be spared from the meal effect to a significant extent.

Abstract: The disclosure relates to a pharmaceutical composition for oral administration, containing, as active principle, a benzofuran derivative having antiarrhythmic activity, in particular dronedarone and the pharmaceutically acceptable salts thereof, and at least one lipid carrier, said pharmaceutical composition being intended to be used in unit dosage form of the capsule type, in particular with a hard shell. This pharmaceutical composition and the dosage form comprising such a composition aim to limit the meal time effect following oral administration in humans. The lipid carrier allows: the solubilization of the active principle of the invention; and the shielding thereof from the negative effects of pH in the intestinal tract, thereby allowing same to be spared from the meal effect to a significant extent.

Abstract: The disclosure relates to a pharmaceutical composition for oral administration, containing, as active principle, a benzofuran derivative having antiarrhythmic activity, in particular dronedarone and the pharmaceutically acceptable salts thereof, and at least one lipid carrier, said pharmaceutical composition being intended to be used in unit dosage form of the capsule type, in particular with a hard shell. This pharmaceutical composition and the dosage form comprising such a composition aim to limit the meal time effect following oral administration in humans. The lipid carrier allows: the solubilization of the active principle of the invention; and the shielding thereof from the negative effects of pH in the intestinal tract, thereby allowing same to be spared from the meal effect to a significant extent.

Abstract: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

Abstract: this invention discloses and claims a pharmaceutical composition in liquid or semi-liquid form, which is self-emulsifying or self-microemulsifying in aqueous medium, for the oral administration of a pyrazole-3-carboxamide derivative, in which said derivative is dissolved in an amphiphilic mixture containing one or more lipid solvents and a nonionic hydrophilic surfactant.

Abstract: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

Abstract: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.

Abstract: This invention discloses and claims a pharmaceutical composition in liquid or semi-liquid form, which is self-emulsifying or self-microemulsifying in aqueous medium, for the oral administration of a pyrazole-3-carboxamide derivative, in which said derivative is dissolved in an amphiphilic mixture containing one or more lipid solvents and a nonionic hydrophilic surfactant.

Abstract: The pharmaceutical formulations according to the invention contain from 0.5 to 50% by weight of a cyclic quaternary ammonium compound and pharmaceutically appropriate excipients and are formulated by wet granulation, preferably with polysorbate 80.

Abstract: The invention relates to a pharmaceutical composition for parenteral administration, characterized in that it comprises:from 1.5 to 8% by weight of an active principle consisting of amiodarone or one of the pharmaceutically acceptable salts thereofa physiologically acceptable buffer solution capable of solubilizing the active principle and of maintaining the pH of the composition between 2.4 and 3.8a nonionic hydrophilic surfactant.

Abstract: The present invention relates to a process for the synthesis of a monohaloalkylferrocene by reaction of hydrogen with a monohaloalkanoylferrocene in the presence of PtO.sub.2 and SnCl.sub.2 as catalyst in an acetic acid medium.In this manner, a crude, particularly pure synthetic product is obtained in a high yield, simply and inexpensively.The monohaloalkylferrocenes are especially useful as surfactants or as intermediates for the synthesis of combustion catalysts for propergols.The present invention also relates to a novel monohaloalkylferrocene, namely 4-chlorobutylferrocene.

Abstract: The present invention relates to a process for the synthesis of monohaloalkanoylferrocenes of general formula (I) ##STR1## in which X=Cl, Br, n is an integer such that 2.ltoreq.n.ltoreq.7, R.sub.1 and R.sub.2 =H, C.sub.1 -C.sub.8 alkyl chain. A ferrocene derivative of general formula (II) ##STR2## in which R.sub.1 and R.sub.2 have the abovementioned meaning, is reacted at a temperature -5.degree. C.<.theta..sub.r <+15.degree. C., in the presence of AlCl.sub.3 with a halide or the anhydride of an acid of general formula (III) HOOC--(CH.sub.2).sub.n --X, X and n having the abovementioned meaning. An acylating solution obtained by mixing AlCl.sub.2 and the acid halide or anhydride in CH.sub.2 Cl.sub.2, whose temperature .theta..sub.a is such that 5.degree. C..ltoreq..theta..sub.r -.theta..sub.a .ltoreq.15.degree. C., is progressively added to a solution of the ferrocene derivative (II) in CH.sub.2 Cl.sub.2. The molar ratio of the acid halide or anhydride to the ferrocene derivative is between 0.99 and 1.

Abstract: The invention relates to a process for the preparation of conductive polymers or prepolymers and to conductive polymers or prepolymers.The process of the invention consists of reacting a polymer containing ethylenic unsaturations such as a hydroxytelechelic polybutadiene with a silane compound of formula ##STR1## in which R.sub.1 denotes a hydrocarbon group containing at least one heteroatom bearing mobile electrons, such as the oxygen of an ether group, andR.sub.2 and R.sub.3 denote a substituted or unsubstituted organic residue or a group R.sub.1.The polymer obtained is precipitated by the addition of a compound which is not a solvent for the polymer, and is separated from the reaction medium.The polymers obtained have an electrical conductivity which is multiplied by a factor of 10.sup.5 relative to the unmodified polymer.The present invention applies in particular in the field of the polymer industry.

Abstract: Liquid/liquid extraction process for copper from an aqueous sulphuric acid solution acting on the concentrated mineral or semi-finished product to be treated.The extraction is carried out in an organic solvent containing in solution an extraction agent derived from 2-phenyl-4-acyl-(3H)-pyrazol-3-ones, with the phenyl group substituted or unsubstituted.Application to the upgrading of minerals.

Abstract: Liquid/liquid extraction process for copper from an aqueous sulphuric acid solution acting on the concentrated mineral or semi-finished product to be treated.The extraction is carried out in an organic solvent containing in solution an extraction agent derived from 2-phenyl-4-acyl-(3H)-pyrazol-3-ones, with the phenyl group subsitituted or unsubstituted.Application to the upgrading of minerals.

Abstract: Aqueous composition for the dispersion of hydrophobic substances, constituted by a microemulsion of one or more hydrocarbons, ketones and alcohols and/or glycol ethers or esters in the presence of a surfactant compound, in water, characterized in that the water has a pH of 8 to 14 and that the molar ratio of the carbonyl groups (--CO--) present to the hydrocarbon is from 0.2 to 1.Application of this composition to the removal of various paints, in particular to washing brushes; washing can be finished with water.

Abstract: The present invention relates to a process for preparing microemulsions between an acid phase and a hydrophobic phase in which a cationic surfactant and a cosurfactant are added to the reaction medium. This process makes it possible to obtain either a microemulsion of acid-in-oil type in equilibrium with an acid phase, or a microemulsion of oil-in-acid type in equilibrium with an organic phase, or a microemulsion in simultaneous equilibrium with the organic and acid phases.The process is applicable to numerous domains: controlled acidification, stimulatiion of oil-producing well formations, fracturing, liquid-liquid extraction of metal cations in hydrometallurgy, chemical reactions (sulfonation, sulfatation, protonic catalysis).

Abstract: Triphosphonic ester, each of the three phosphorus atoms of which is bound to a carbon atom of the same hydrocarbon group, having 2 or 4 free acid functions or two salt functions, is prepared by reacting an alkaline-metal derivative of a phosphite diester with a diphosphonic acid tetra-ester, followed by hydrolysis of the compound obtained. The triphosphonic esters may be used for various known uses of phosphonates, including the extraction of heavy metals.